Leukemia is a type of cancer that affects the blood and bone marrow.
白血病是一种影响血液和骨髓的癌症类型。
He was diagnosed with acute lymphoblastic
leukemia, a severe childhood cancer.
他被诊断为急性淋巴细胞白血病，这是一种严重的儿童癌症。
Treatment for
leukemia often involves chemotherapy and radiation therapy.
白血病的治疗通常包括化疗和放疗。
The patient's
leukemia went into remission after several months of aggressive treatment.
经过几个月的积极治疗，患者的白血病进入了缓解期。
She bravely fought her way through her battle with
leukemia, inspiring many with her strength.
她勇敢地与白血病抗争，以她的坚韧激励了许多人。
A
leukemia survivor shared her story at the charity event to raise awareness and funds for research.
一位白血病幸存者在慈善活动中分享了她的故事，以提高人们对这种疾病的认识并筹集研究资金。
The
leukemia support group provided emotional and practical assistance to those affected by the disease.
白血病支持小组为患病者提供了情感和实际的帮助。
Early detection is crucial in increasing the chances of survival for patients with
leukemia.
早期发现对于白血病患者提高生存率至关重要。
His innovative
leukemia drug showed promising results in clinical trials, bringing hope to millions.
他的创新白血病药物在临床试验中显示出有希望的结果，给数百万人带来了希望。
She dedicated her life to researching
leukemia, hoping to find a cure one day.
她毕生致力于白血病的研究，期待有一天能找到治愈方法。
Suzhou-based domestic biopharmaceutical company Ascentage Pharma said ahead of International Chronic Myeloid Leukemia Day on Wednesday a new application for a drug-resistant CML treatment has been submitted in China.
在周三的国际慢性髓性白血病日之前，苏州本地的生物制药公司Ascentage Pharma表示，已在中国为一种针对药物抵抗性慢性髓性白血病的新型治疗方法提交了新药申请。
A key drug candidate was developed for the treatment of drug-resistant chronic myeloid leukemia, which affects an estimated 10,000 patients in the country each year, said Yang Dajun, chairman and CEO of Ascentage Pharma.
Ascentage Pharma的董事长兼首席执行官杨大俊表示，一个关键的药物候选产品已被开发用于治疗耐药性慢性骨髓性白血病，该疾病每年估计影响全国约1万名患者。
One of the major exhibits at the fair will be its core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML), which afflicts an estimated 10,000 patients in the country each year, Yang said.
杨说,展览会上的主要展品之一是该公司为治疗对药物产生抗性的慢性骨髓性白血病而研制的核心候选药物;每年国内大约有1万名患者罹患这种疾病。
In June, BeiGene's drug Brukinsa received conditional approval in China as a treatment for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least one prior therapy, and as a treatment for adult patients with MCL who have received at least one prior therapy.
今年6月， BeiGene的药物Brukinsa在中国获得有条件批准，用于治疗至少接受过一次治疗的成年慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者，以及至少接受过一次治疗的成年MCL患者。
The drug is for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, and also for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
这款药物适用于已经接受过至少一次先前治疗的成年弥漫性大B细胞淋巴瘤患者，以及成年慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者。
I-Mab is also planning to launch Phase 1/2 trials in China among patients with relapsed or refractory acute myeloid leukemia, or myelodysplastic syndrome.
In addition to its significant anti-tumor activity, the drug demonstrated a favorable safety and tolerability profile," saidxa0Li Jianyong, professor and director of thexa0department of hematologyxa0and director of the Pukou chronic lymphocytic leukemia center at thexa0First Affiliated Hospitalxa0ofxa0Nanjing Medical University.
According to the collaboration framework, three vaccines, including one to treat pneumococcus, and at least seven new medicines, including for treating acute myeloid leukemia and non-small-cell long cancer, which have been approved by the United States Food and Drug Administration and the European Medicines Agency for market launch, will be available in the pilot zone soon.
According to their agreement, they will jointly carry out the phase-3 study to access the safety and efficacy of lisaftoclax (APG-2575), an investigational drug developed by Ascentage Pharma, as first-line treatment in combination with AstraZeneca's Calquence (acalabrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma patients who have not received any treatment.
Seven years ago, Liu's wife suffered from leukemia.
His wife received a successful bone marrow transplant and fully recovered from leukemia, while their two children also got married.
Chinese biotech firm Ascentage Pharma is expecting to expand the indication of its first approved medicine to treat more types of chronic myeloid leukemia patients as soon as this year, as it has already finished several key clinical trials, according to Yang Dajun, chairman and CEO of the company.
Chronic myeloid leukemia, which affects around 20,000 new patients each year in China, is in principle a treatable malignancy, but drug resistance is lowering survival.
Designated as a project under a major national innovative drug development and manufacturing program, the drug is the first of its kind in China and the second in the world with clear global best-in-class potential, as a third-generation treatment for chronic myeloid leukemia harbors the T315I mutation.
The company now owns an 8,000 sq m manufacturing base for developing Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T)－a tumor immunotherapy mainly applied to leukemia and lymphoma－and has so far obtained 3 CAR-T official approvals to initiate clinical trials.
该公司目前拥有8000平方米的制造基地，用于开发嵌合抗原受体T细胞免疫疗法（CAR-T）-主要用于白血病和淋巴瘤的肿瘤免疫疗法-迄今为止已获得3项CAR-T官方批准，以启动临床试验。
The company currently has several products in the pipeline for lung cancer and leukemia, among other maladies.
该公司目前在肺癌和白血病等疾病方面有几种产品在研发中。
Pharmaceutical companies such as AbbVie Pharmaceutical Trading (Shanghai) Co Ltd, whose acute myeloid leukemia medication is covered by the insurance, welcome the new initiative, saying it will bring more treatment methods and products to help relieve pain and improve the quality of life for Chinese patients, said officials with the pilot zone.
据试点区官员表示，像艾伯维上海生物医药贸易有限公司这样的制药企业对新举措表示欢迎。艾伯维公司的急性髓系白血病药物已被纳入保险覆盖范围。他们认为，这一举措将带来更多治疗手段和产品，有助于减轻中国患者的痛苦，提高他们的生活质量。
In July 2020, Brukinsa was approved by the NMPA for two indications-mantle cell lymphoma and chronic lymphocytic leukemia.
In July 2020, Brukinsa was approved by the NMPA for two indications-mantle cell lymphoma and chronic lymphocytic leukemia.'的中文翻译为：'2020年7月，布鲁金莎被NMPA批准用于两种适应症- mantle细胞淋巴瘤和慢性淋巴细胞性白血病。
New drug applications to China's National Medical Products Administration for relapsed or refractory MCL in August 2018, and for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, later in October 2018, have been accepted and granted priority review.
Besides offering comprehensive insurance, the product also puts special emphasis on children's critical illnesses, such as childhood leukemia, reported in 15,000 patients in China each year, he added.
He passed away due to leukemia and multiple organ failure in Shanghai on Wednesday at the age of 96.
Letter to the entire Party, military and people hails him as an outstanding leaderJiang Zemin passed away due to leukemia and multiple organ failure in Shanghai at 12:13 pm on Nov 30, 2022, at the age of 96, it was announced on Wednesday.
The letter says they proclaim with profound grief to the whole Party, the entire military and the Chinese people of all ethnic groups that our beloved Comrade Jiang Zemin died of leukemia and multiple organ failure after all medical treatments had failed.
未经许可，严禁转发。QQ交流群：688169419